Joining Forces: Focusing on the Frontier, Creating Value Together
On June 11, 2025, Hangzhou Qiantang Longyue Biotech Co., Ltd. and Medgen Life Science (Shenzhen) Co., Ltd. officially signed a strategic cooperation agreement.
Qiantang Longyue and Medgen Life Science will integrate their respective core advantages in precision medical devices and biomaterials to jointly advance innovative product R&D and industrialization. The partnership focuses on frontier technologies in biomaterials and precision medicine, aiming to inject new momentum into the healthcare sector, deliver superior solutions for clinicians and patients worldwide, and open a new chapter of mutual success.
About Qiantang Longyue
Hangzhou Qiantang Longyue Biotech Co., Ltd. is an innovative medical enterprise specializing in professional drug delivery system solutions for clinical treatment. The company's R&D, manufacturing, and quality management teams have over 20 years of deep experience in the medical device field, with extensive technical expertise in novel drug delivery systems, premium pharmaceutical packaging materials, and innovative drug-device combination products. The company's quality management system meets FDA (QSR820), NMPA, and EU (ISO 13485) requirements. It collaborates with numerous leading domestic pharmaceutical companies on developing novel drug delivery systems and drug-device combination products, committed to improving healthcare quality and public health.
About Medgen Life Science
Medgen Life Science is a National High-Tech Enterprise supported by two core technology platforms: hydroxyapatite regenerative conversion and biomedical collagen. The company focuses on inducible regenerative biomaterials and active regenerative repair, advancing the application and development of advanced biomedical materials and regenerative medicine in orthopedics, dentistry, medical aesthetics, and sports medicine.
From November 2024 to January 2025, Medgen Life Science completed two consecutive funding rounds totaling nearly RMB 100 million. In November 2024, the company received an exclusive Series A investment of tens of millions of RMB from Huaxi Yuanyou Fund for regenerative repair material product line R&D and commercialization. In January 2025, it received an exclusive Series A+ investment of tens of millions of RMB from Yuansheng Venture Capital, with funds focused on advancing medical aesthetics product clinical trials and orthopedic product post-launch sales. Changhai Capital served as exclusive financial advisor for both rounds.